Acorda Therapeutics, Inc. - Product Pipeline Review - 2014

Global Markets Direct
April 30, 2014
58 Pages - GMD12090
$1,500.00

Summary

Global Markets Direct’s, ‘Acorda Therapeutics, Inc. - Product Pipeline Review - 2014’, provides an overview of the Acorda Therapeutics, Inc.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Acorda Therapeutics, Inc.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Acorda Therapeutics, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Acorda Therapeutics, Inc.’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the Acorda Therapeutics, Inc.’s pipeline products

Reasons to buy

- Evaluate Acorda Therapeutics, Inc.’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Acorda Therapeutics, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Acorda Therapeutics, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Acorda Therapeutics, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Acorda Therapeutics, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Acorda Therapeutics, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

'

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Acorda Therapeutics, Inc. Snapshot 5
Acorda Therapeutics, Inc. Overview 5
Key Information 5
Key Facts 5
Acorda Therapeutics, Inc. - Research and Development Overview 6
Key Therapeutic Areas 6
Acorda Therapeutics, Inc. - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Pipeline Products - Partnered Products 11
Partnered Products/Combination Treatment Modalities 12
Acorda Therapeutics, Inc. - Pipeline Products Glance 13
Acorda Therapeutics, Inc. - Late Stage Pipeline Products 13
Pre-Registration Products/Combination Treatment Modalities 13
Phase III Products/Combination Treatment Modalities 14
Acorda Therapeutics, Inc. - Clinical Stage Pipeline Products 15
Phase II Products/Combination Treatment Modalities 15
Phase I Products/Combination Treatment Modalities 16
Acorda Therapeutics, Inc. - Early Stage Pipeline Products 17
Preclinical Products/Combination Treatment Modalities 17
Acorda Therapeutics, Inc. - Drug Profiles 18
diazepam 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
capsaicin 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
dalfampridine ER 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
AC-105 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
NP-1998 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
cimaglermin alfa 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
rHIgM-22 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Enzyme To Inhibit Chondroitin Sulfate Proteoglycan For Spinal Cord Injury And Brain Injury 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Tenascin-C Fragments For Spinal Cord Injury 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Acorda Therapeutics, Inc. - Pipeline Analysis 33
Acorda Therapeutics, Inc. - Pipeline Products by Target 33
Acorda Therapeutics, Inc. - Pipeline Products by Route of Administration 35
Acorda Therapeutics, Inc. - Pipeline Products by Molecule Type 36
Acorda Therapeutics, Inc. - Pipeline Products by Mechanism of Action 37
Acorda Therapeutics, Inc. - Recent Pipeline Updates 39
Acorda Therapeutics, Inc. - Dormant Projects 48
Acorda Therapeutics, Inc. - Company Statement 49
Acorda Therapeutics, Inc. - Locations And Subsidiaries 56
Head Office 56
Other Locations & Subsidiaries 56
Appendix 57
Methodology 57
Coverage 57
Secondary Research 57
Primary Research 57
Expert Panel Validation 57
Contact Us 58
Disclaimer 58

List of Tables
Acorda Therapeutics, Inc., Key Information 5
Acorda Therapeutics, Inc., Key Facts 5
Acorda Therapeutics, Inc. - Pipeline by Indication, 2014 7
Acorda Therapeutics, Inc. - Pipeline by Stage of Development, 2014 9
Acorda Therapeutics, Inc. - Monotherapy Products in Pipeline, 2014 10
Acorda Therapeutics, Inc. - Partnered Products in Pipeline, 2014 11
Acorda Therapeutics, Inc. - Partnered Products/ Combination Treatment Modalities, 2014 12
Acorda Therapeutics, Inc. - Pre-Registration, 2014 13
Acorda Therapeutics, Inc. - Phase III, 2014 14
Acorda Therapeutics, Inc. - Phase II, 2014 15
Acorda Therapeutics, Inc. - Phase I, 2014 16
Acorda Therapeutics, Inc. - Preclinical, 2014 17
Acorda Therapeutics, Inc. - Pipeline by Target, 2014 34
Acorda Therapeutics, Inc. - Pipeline by Route of Administration, 2014 35
Acorda Therapeutics, Inc. - Pipeline by Molecule Type, 2014 36
Acorda Therapeutics, Inc. - Pipeline Products by Mechanism of Action, 2014 38
Acorda Therapeutics, Inc. - Recent Pipeline Updates, 2014 39
Acorda Therapeutics, Inc. - Dormant Developmental Projects,2014 48
Acorda Therapeutics, Inc., Subsidiaries 56

List of Figures
Acorda Therapeutics, Inc. - Pipeline by Top 10 Indication, 2014 7
Acorda Therapeutics, Inc. - Pipeline by Stage of Development, 2014 9
Acorda Therapeutics, Inc. - Monotherapy Products in Pipeline, 2014 10
Acorda Therapeutics, Inc. - Pipeline by Top 10 Target, 2014 33
Acorda Therapeutics, Inc. - Pipeline by Top 10 Route of Administration, 2014 35
Acorda Therapeutics, Inc. - Pipeline by Top 10 Molecule Type, 2014 36
Acorda Therapeutics, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2014 37

$1,500.00

Research Assistance

We can help you find
data and analyses
relevant to your needs,
or prepare a custom report.

info@LMRreports.com
+1 212 564 2838
+1 212 564 8133 fax

Custom Research

Need a custom report
tailored to your goals and budget? 

E-mail us your project outline
or call Client Services to speak
with your industry analyst.

info@LMRreports.com
+1 212 564 2838
+1 212 564 8133 fax

Discount Codes

Request Discount Codes
for reports of interest to you.

info@LMRreports.com
+1 212 564 2838
+1 212 564 8133 fax